ADC Therapeutics SA Share Price & Technical Analysis
ADCT · $3.38 (-0.59%)
Healthcare / Biotechnology
$3.38
-0.59%
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatmen…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-11% return in May, 40% avg return in past 3 year May month.
-2% return in 2026, 47% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 14% | -5% | 0% | -11% | – | – | – | – | – | – | – | -2% |
| 25 | -15% | 13% | -22% | 0% | 121% | -13% | 4% | 15% | 29% | 15% | -2% | -17% | 128% |
| 24 | 82% | 50% | -8% | -4% | -23% | -6% | 3% | -12% | 7% | -12% | -17% | -20% | 39% |
| 23 | 34% | -31% | -47% | -5% | 21% | -4% | -29% | -20% | -25% | -22% | 14% | 89% | -25% |
| 22 | -21% | 5% | -12% | -20% | -41% | 14% | -7% | -8% | -29% | -10% | -18% | 3% | -146% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$429.27M
P/E ratio
—
52W high
$4.98
52W low
$2.04
Volume
2,49,356
Beta
1.84
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is ADC Therapeutics SA share price today?
- ADC Therapeutics SA (ADCT) last traded around $3.38 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ADCT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ADCT. Download the app for real-time alerts.
- How can I analyze ADC Therapeutics SA stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.